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Abstract 
A series of compounds containing the N-hydroxyoxindole scaffold were synthesized and evaluated 
for their antitumor activity. The compounds showed a potent antiproliferative activity against wild-
type p53 IGROV-1 ovarian carcinoma cell line and a considerably lower efficacy against the mutant 
IGROV-1/Pt1 subline lacking p53 function. The differential response of ovarian carcinoma cells 
depending on p53 status was  also reflected in the different susceptibility to apoptosis of the treated 
cell lines. The results support a role of this transcription factor as a determinant of  cytotoxicity. 
The therapeutic potential of the most representative compound of the series was evaluated in the 
treatment of an IGROV-1 xenograft growing as ascitic tumor. Using i.p. administration, daily 
treatment with the compound for 3 weeks produced a significant increase of survival of tumor- 
bearing animals. 
 
 
The easily available 3-(hetero)arylidene-oxindoles[1] are a privileged scaffold for compounds 
endowed with a variety of biological properties, mainly antitumor, but also antibacterial,[2,3] 
antifungal,[2] cardiotonic[4] and antioxidative.[5] The antitumor activity appears to be mediated by 
different mechanisms, mainly inhibition of kinases. [6-13] 
A very significant  result of these studies was the development of Sunitinib malate (Sutent®, Pfizer) 
[14]
, an inhibitor of receptor tyrosine kinases, which was approved in 2006 for the treatment of 
gastrointestinal stromal tumours and advanced renal-cell carcinoma. 
Differently from the oxindoles, the corresponding N-hydroxy analogues have been considerably 
less studied. To the best of our knowledge, only a few examples of biologically active N-hydroxy 
oxindoles have been reported in the literature so far. Compounds containing this scaffold were 
studied as influenza virus[15] and Ret tyrosine kinase [12] inhibitors as well as for the treatment of 
Multiple Sclerosis.[16] 
As part of a previous research program aimed at studying new HDAC inhibitors, we have 
developed a series of hydroxamic acid-based compounds, characterized by a cinnamic spacer 
capped with a substituted phenyl group (1, Figure 1).[17] Recently, we have initiated the search for 
ZBG (Zinc binding group)-functionalities that could replace the hydroxamic acid group[18]  
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Figure 1. General structure of HDAC inhibitors 1 containing the 4-vinylbiphenyl scaffold and structures of compounds 
2 and 3a. 
 
Among the analogues incorporating alternative ZBGs, we synthesized compound 2 containing a 5-
membered cyclic hydroxamic acid.[18]  
Unfortunately, compound 2 showed a lack of activity in terms of both HDAC inhibition (IC50 >5 
µM on HDAC-2 from HeLa cells) and cell growth inhibition (IC50>20 µM against a panel of tumor 
cell lines). Therefore, we replaced the hydroxypyrrolidinone moiety with a N-hydroxyoxindole 
counterpart (compound 3a). While showing a very low activity on the enzyme (IC50 >5 µM on 
HDAC-2 from HeLa cells) as much as 2, the new derivative 3a had a potent cell growth inhibitory 
activity on IGROV-1 (IC50 0.1+0.05 µM ) and HCT 116 (IC50 1.3+0.1 µM)  tumor cell lines. We 
speculated that this activity could be due to the N-hydroxyoxindole core, thus we decided to 
investigate this promising and almost unstudied scaffold. A series of analogues containing the N-
hydroxyoxindole skeleton were synthesized and their biological activity was evaluated. Here we 
show the results of this preliminary exploration. Compounds 3a-g were prepared by Knoevenagel 
condensation onto 1-hydroxy-1,3-dihydroindol-2-one 5, in turn obtained from methyl 2-
nitrophenylacetic acid[19] by reduction with Zn/NH4Cl.[20] Compound 3h was obtained by 
methylation of compound 3a. (Scheme 1). 
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Figure 2. Structures of compounds 3a-h 
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Scheme 1. Synthesis of compounds 3a-h. Reagents and conditions: a) Zn, NH4Cl, CH3OH, H2O, rt, 1.5h, 50%; b) 
RCHO, EtOH, piperidine, reflux, 1-5h, 30-85%; c) K2CO3, CH3CN, methyl iodide, reflux, 6 h, 58%. 
 
The N-hydroxyoxindoles 3a-h were obtained as mixtures of E/Z isomers. 
NOE experiments on a series of 3-arylideneoxindoles demonstrated that the chemical shifts of the 
ortho protons of the benzylidene ring were around 7.8-8.5 ppm for the Z isomer and 7.4-7.8 ppm for 
the E isomer.[21] Analogously, to determine the E/Z stereochemistry of compounds 3 we conducted 
NOE experiments on compound 3a (see SI), confirming that the ortho protons of the benzylidene 
ring in the Z isomer are deshielded relative to those of the E isomer. Thus, the relative ratios of the 
E and Z stereoisomers within this N-hydroxyoxindole series (compounds 3a-f, 3h) was assigned 
based on the chemical shifts of protons at the C-2’ and C-6’ positions. On the contrary, the 
configuration of compound 3g was assigned based on the chemical shift of proton  H-2’ on the 
phenylallylidene moiety. [22]  
Previous investigations on 3-arylideneoxindoles have reported the E/Z isomerization to be solvent, 
temperature, time and light dependent. [21-24] To determine the stability of our compounds over time, 
we separated the two isomers of 3a by flash column chromatography. The isomerization was 
studied by 1H NMR spectroscopy, as this method can be carried out quantitatively in real-time. 
Freshly prepared solutions of both isomers in DMSO-d6 were monitored at various time intervals, 
evaluating the chemical shift of the benzylidene ring ortho protons. The results evidenced that 
equilibration occurred within 3 h. Thus, it is reasonable to assume that the N-hydroxyoxindoles, 
prepared in DMSO stock solution, would be mixtures of E/Z isomers when tested in biological 
assays. 
 
The prepared compounds were tested for antiproliferative activity against IGROV-1 and its subline 
IGROV-1/Pt1 (human ovarian carcinoma cell lines) selected for resistance to Cisplatin (Table 1), 
the former having functional p53, whereas the latter is p53-defective. N-hydroxyindolinone 3a 
exhibited a potent antiproliferative activity against IGROV-1 cells and a considerably lower 
inhibitory activity against the mutant IGROV-1/Pt1 subline lacking p53 function. 
  
Table 1. Antiproliferative activity (IC50, µM) of compounds 3a-h against IGROV-1 and IGROV-1/Pt1 cell lines 
 
Cpd IC50 (µM) E:Z 
 IGROV-1 IGROV-1/Pt1  
3a  0.1+0.1 6.6+1 8:2 
3b  2.62+0.49 38.95+1.63 8:2 
3c  12.7+3.5 36.8+3.5 9:1 
3d  0.23 5.6+0.7 8:2 
3e  7.8+1.8 20.3 9:1 
3f  2.4+0.6 12.9+1.1 5:95  
3g  3.7+1.1 12.2+4.3 5:95[a] 
3h  1.65+0.9 15.05 95:5 
 
[a]
 ratio ZE: EE 95:5 [22] 
 
All the analogues 3b-g exhibited a significant antiproliferative activity against IGROV-1 cells with 
IC50 values in the micromolar range (Table 1). The introduction of a N-methoxy group in place of 
the N-hydroxy group caused a decrease of the activity (3h vs 3a). A common feature of the 
compounds of this series was a differential inhibitory activity against IGROV1/Pt1 subline lacking 
p53 function (Table 1). Compound 3a, the most active of the series, was chosen to further 
investigate this feature. The compound was tested on A431 cells (from a squamous cell carcinoma) 
characterized by p53 mutation. The reduced sensitivity of these cells to 3a was consistent with the 
influence of the p53 function on the cytotoxic activity. (Figure 3). 
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Figure 3. Dose-response curves for IGROV-1, IGROV-1/Pt1 and A431 tumor cell lines treated for 72h with compound 
3a. 
 
The differential response of the two ovarian carcinoma cell lines was also reflected in the different 
susceptibility to apoptosis induced by cytotoxic concentrations (IC80) of 3a (Figure 4).  
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Figure 4. Flow cytometric analysis of apoptosis induced after the exposure to compound 3a (IC80 value) in ovarian 
carcinoma cells IGROV-1 and ovarian carcinoma cells IGROV-1/Pt1
.
 The extent of apoptosis was determined 72 h 
after drug exposure by TUNEL assay. 
 
The wild type p53cells were more susceptible to apoptosis induction (apoptosis level about 30% 
after 72 h exposure) than the p53 mutant cells (apoptosis level about 17%) in spite of exposure to 
high concentration (10 µM). The ability to induce apoptosis was also consistent with the substantial 
increase of sub-G1 function of treated cells (Figure 5). Following a short term (4 h) exposure, 
compound 3a was able to induce p53 activation, as detected by p53 protein phosphorylation and 
acetylation (Figure 5). 
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Figure 5. a) Effects of compound 3a on acetylation, phosphorylation of p53 and activation of histone γH2AX in 
IGROV-1 cells. Cells were treated for 4h with cytotoxic concentration (3µM, IC80) of compound 3a . Cell lysates were 
prepared and examined by western-blot analysis. The blots were reprobed with β-tubulin as a loading control. b) Cell 
cycle perturbation induced after the exposure to compound 3a (IC80 and IC50 value) in ovarian carcinoma cells IGROV-
1.
.
 Time course analysis of cell cycle was performed by propidium-iodide staining. 
 
All these results support a role of p53 in response to treatment with N-hydroxyoxindoles. 
A number of compounds are known to enhance the function of wild-type p53 by increasing its 
stability through various mechanisms.[25] Most of them (nutlins, benzodiazepinediones and spiro-
oxindoles) act by targeting the MDM2:p53 interaction. Noteworthy, a recent work has demonstrated 
that 3-arylideneoxindoles inhibit the MDM2-p53 interaction.[26] All these considerations led us to 
speculate that 3-arylidene-N-hydroxyindolin-2-ones could interact with the p53 binding site on 
MDM2. 
MDM2 protein has been extensively studied in more than 30 high resolution X-ray and nuclear 
magnetic resonance (NMR) structures with and without p53-derived peptides and small molecules. 
Analysis of all available complexes showed the p53 binding site to be relatively unchanging, 
displaying no major induced fit. MDM2 shows on its surface a deep and structured binding site for 
p53, mainly constituted by three hydrophobic pockets occupied by the “hot-spot triad” made up by 
p53's W23, L26 and F19 (Figure 6A). All three hydrophobic amino acids undergo multiple van der 
Waals contacts with the surrounding MDM2's residues, while W23 forms an additional hydrogen 
bond with the Leu54 backbone carbonyl group. 
In order to explain the biological activity of compounds 3a-h and to investigate the possible 
interaction of such compounds with the p53 binding site on MDM2, molecular docking studies have 
been performed. In details, the X-ray crystal structure of the 109-residue amino-terminal domain of 
MDM2 in complex with the 15-residue transactivation domain peptide of p53 has been retrieved 
from RCSB Protein Data Bank (PDB code 1YCR).[27] p53 fragment was removed from the complex 
and the MDM N-terminal region was prepared for the docking procedure by using the Protein 
Preparation Wizard[28] protocol implemented in Maestro.[29] All compounds were drawn and 
prepared by using the LigPrep module.[30] For all the compounds both the Z and E isomers were 
considered. Docking studies were performed by using Glide[31, 32] software.  
Our results show that N-hydroxyoxindoles interact with the p53 cleft on MDM2 with a reasonable 
binding mode. In Figure 6B the best docking pose found for the most active compound 3a has been 
reported. The oxindole moiety occupies the W23 pocket on MDM2, while the R2 substitution 
partially overlaps the position of F19. A hydrogen bond occurs between the NH group of the core 
scaffold and the carbonyl oxygen of L54, resembling the hydrogen bond found between W23 from 
p53 and L54. 
 
  
Figure 6. A) Molecular interactions between p53 (orange cartoon) and MDM2 (violet cartoon). L54 has been shown in 
sticks. Hydrogen bonds are represented as yellow dashes. B) Superimposition between p53 and the docking pose of 
compound 3a. The hydrogen bond between 3a and the backbone carbonyl group of L54 is represented as yellow dashes.  
 
Compound 3a was chosen to evaluate the therapeutic potential in the treatment of IGROV-1 
xenograft growing as ascitic tumor. Using i.p. administration, daily treatment  with 3a (10 mg/kg, 
qd x 5 day/week) for 3 weeks, produced an appreciable increase (40%) of survival of tumor-bearing 
animals (data not shown). The efficacy of the treatment was also evidenced by a delay in ascites 
onset  (Figure 7). 
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Figure 7. Disease onset in athymic nude mice bearing ascitic ovarian carcinoma IGROV-1 treated i.p. with 3a (10 
mg/kg, qd x 5 day/week) for 3 weeks. 
 
In conclusion, a series of compounds containing the N-hydroxyoxindole scaffold showed a potent 
antiproliferative activity against IGROV-1 cells and a considerably lower inhibitory activity against 
the mutant IGROV-1/Pt1 subline lacking p53 function. Biochemical analysis of cells treated with 
the most active compound did not detect appreciable modifications of H3 or H4 histones or tubulin 
acetylation. However, the results indicated activation of p53 and apoptosis induction in response to 
drug treatment. It is well known that the functional wild-type p53 plays a role in the control of 
tumor growth. Efficacy of antitumor therapy often correlates with cell ability to activate p53 
dependent apoptosis. In contrast, loss of p53 function may confer resistance to various antitumor 
agents. Although the molecular pathways involved in modulation of p53 remain to be defined, 
optimization of the molecules described in our study may have therapeutic implications. Further 
biological tests and SAR studies on this new series of compounds are currently underway, in the 
perspective of a potential development. 
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